Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Johanna A. Kremer Hovinga, MD Prof, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD, Ara Metjian, MD

Blood (2018) 132 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2018-99-112177

Published: 2018

Journal Articles

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi, MD PhD, Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 373.

https://doi.org/10.1182/blood-2018-99-112125

Published: 2018

Journal Articles

Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD)

Matthew Bostic, BS, MS, Qiuhong Zhao, MS, Sarah A Wall, MD, Spero R Cataland, MD, Sumithira Vasu, MD MBBS

Blood (2018) 132 (Supplement 1): 4572.

https://doi.org/10.1182/blood-2018-99-114892

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Paul Knöbl, MD PhD, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2018-99-112174

Published: 2018

Journal Articles

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Marie Scully, MD, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD, Ara Metjian, MD, Javier de la Rubia, MD, Katerina Pavenski, MD, Filip Callewaert, PhD, Debjit Biswas, PhD, Hilde De Winter, MD, Robert K. Zeldin, MD

Blood (2017) 130 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-1.LBA-1

Published: 2017

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Factors Associated with Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Results from the United States Thrombotic Microangiopathy TTP Registry

Todd Clover, MD MS, Ronald S. Go, MD, Ana G. Antun, MD, Spero R Cataland, MD, Shruti Chaturvedi, MBBS,MS, Elizabeth Davis, Andrew Johnson, MD, Ming Yeong Lim, MBBChir, Meera Sridharan, MD, Keith McCrae, MD, J. Evan Sadler, MD PhD, Marshall A. Mazepa, MD, Lisa Baumann-Kreuziger, MS MD

Blood (2017) 130 (Supplement 1): 3624.

https://doi.org/10.1182/blood.V130.Suppl_1.3624.3624

Published: 2017

Journal Articles

The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry

Meera Sridharan, MD, Ana G Antun, MD, Lisa Baumann Kreuziger, Assistant Professor. MD MS, Spero R Cataland, MD, Shruti Chaturvedi, MBBS,MS, Todd Clover, MD, Elizabeth Davis, Andrew Johnson, MD, Keith McCrae, MD, Ming Yeong Lim, MBBChir, J. Evan Sadler, MD PhD, Marshall A. Mazepa, MD, Ronald S Go, MD

Blood (2017) 130 (Supplement 1): 3620.

https://doi.org/10.1182/blood.V130.Suppl_1.3620.3620

Published: 2017

Journal Articles

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Blood (2017) 130 (Supplement 1): 4483.

https://doi.org/10.1182/blood.V130.Suppl_1.4483.4483

Published: 2017

Journal Articles

Prediction of Relapse Based on Remission ADAMTS13 Activity in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias Castanon, MD, Clare Stevens, BS/CCRP, Lauren Jay, Haiwa Wu, Michael McGookey, Jian Chen, MD, James N. George, MD, Shangbin Yang, PhD, Spero R Cataland, MD

Blood (2017) 130 (Supplement 1): 4843.

https://doi.org/10.1182/blood.V130.Suppl_1.4843.4843

Published: 2017

Journal Articles

A Descriptive Analysis of the Demographics and Presenting Symptoms of Patients in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry

Elizabeth Davis, Ana G. Antun, MD, Lisa Baumann Kreuziger, MD MS, J. Evan Sadler, MD PhD, Spero R Cataland, MD, Meera Sridharan, MD, Todd Clover, MD, Andrew Johnson, MD, Keith McCrae, MD, Shruti Chaturvedi, MBBS,MS, Ronald S. Go, MD, Ming Yeong Lim, MBBChir, Marshall A. Mazepa, MD

Blood (2017) 130 (Supplement 1): 1049.

https://doi.org/10.1182/blood.V130.Suppl_1.1049.1049

Published: 2017

Journal Articles

No Major Differences in Outcomes Between the Initial and Relapse Episodes in Patients with Thrombotic Thrombocytopenic Purpura: The Experience from the Ohio State University Registry

Camila Masias Castanon, MD, Haiwa Wu, Michael McGookey, Lauren Jay, Haifeng Wu, MD, Spero R Cataland, MD, Shangbin Yang, PhD

Blood (2016) 128 (22): 2544.

https://doi.org/10.1182/blood.V128.22.2544.2544

Published: 2016

Journal Articles

Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review

Payal C. Desai, MD, Nicole Kendel, MS, Spero R Cataland, MD, Eric H. Kraut, MD, Ying Huang, MA, MS, Subha Raman, MD

Blood (2015) 126 (23): 2189.

https://doi.org/10.1182/blood.V126.23.2189.2189

Published: 2015

Journal Articles

Time-Dependent Activation of Complement system during Storage of Platelet Product

Jian Chen, MD PhD, Shangbin Yang, PhD, Spero R Cataland, MD, Haifeng M Wu, MD

Blood (2014) 124 (21): 4287.

https://doi.org/10.1182/blood.V124.21.4287.4287

Published: 2014

Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Pediatric and Adult Patients with or without Identified Genetic Complement Mutations or Complement Factor H Autoantibodies

Spero R Cataland, MD, Thorsten Feldkamp, MD, Camille L. Bedrosian, MD, John Kincaid, MD MA, Enrico E. Minetti, MD

Blood (2014) 124 (21): 2789.

https://doi.org/10.1182/blood.V124.21.2789.2789

Published: 2014

Journal Articles

Headache Prevalence Following Recovery from TTP and aHUS: A Single-Center, Cross Sectional Cohort Survey Study

Jennifer N Saultz, DO, Haifeng M Wu, MD, Spero R Cataland, MD

Blood (2014) 124 (21): 4826.

https://doi.org/10.1182/blood.V124.21.4826.4826

Published: 2014

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Spero R Cataland, MD, Flora Peyvandi, MD, PhD, Pier M. Mannucci, MD, Bernhard Lämmle, Johanna A Kremer Hovinga, MD, Samuel J Machin, Marie Scully, Gail Rock, PhD, MD, FRCP, James Gilbert, MD, Paul Knoebl, Shangbin Yang, PhD, Haifeng Wu, M.D., Bernd Jilma, MD

Blood (2010) 116 (21): 726.

https://doi.org/10.1182/blood.V116.21.726.726

Published: 2010

Journal Articles

ADAMTS13 Antigen Levels and the Risk of Relapse during Long-Term Clinical Follow Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura.

Spero R. Cataland, MD, Ming Jin, PhD, Shili Lin, PhD, Melanie Kennedy, MD, Eric H. Kraut, MD, James N. George, MD, Haifeng M. Wu, MD

Blood (2007) 110 (11): 3204.

https://doi.org/10.1182/blood.V110.11.3204.3204

Published: 2007

Journal Articles

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Spero R. Cataland, MD, Eric H. Kraut, MD, Don Benson, MD, PhD, Amy K. Ferketich, PhD, April Horne, Ming Jin, PhD, James N. George, MD, Haifeng M. Wu, MD

Blood (2006) 108 (11): 1056.

https://doi.org/10.1182/blood.V108.11.1056.1056

Published: 2006

NARROW

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD)

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Factors Associated with Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Results from the United States Thrombotic Microangiopathy TTP Registry

The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Prediction of Relapse Based on Remission ADAMTS13 Activity in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

A Descriptive Analysis of the Demographics and Presenting Symptoms of Patients in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry

No Major Differences in Outcomes Between the Initial and Relapse Episodes in Patients with Thrombotic Thrombocytopenic Purpura: The Experience from the Ohio State University Registry

Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review

Time-Dependent Activation of Complement system during Storage of Platelet Product

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Pediatric and Adult Patients with or without Identified Genetic Complement Mutations or Complement Factor H Autoantibodies

Headache Prevalence Following Recovery from TTP and aHUS: A Single-Center, Cross Sectional Cohort Survey Study

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

ADAMTS13 Antigen Levels and the Risk of Relapse during Long-Term Clinical Follow Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura.

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only